CVKD vs. TSVT, BDTX, IVA, CABA, NVCT, RENB, CRBU, CRBP, MIST, and VTYX
Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include 2seventy bio (TSVT), Black Diamond Therapeutics (BDTX), Inventiva (IVA), Cabaletta Bio (CABA), Nuvectis Pharma (NVCT), Renovaro (RENB), Caribou Biosciences (CRBU), Corbus Pharmaceuticals (CRBP), Milestone Pharmaceuticals (MIST), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry.
Cadrenal Therapeutics vs.
2seventy bio (NASDAQ:TSVT) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
2seventy bio has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
2seventy bio received 19 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 52.08% of users gave 2seventy bio an outperform vote.
Cadrenal Therapeutics has lower revenue, but higher earnings than 2seventy bio. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
2seventy bio currently has a consensus price target of $7.20, suggesting a potential upside of 175.86%. Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 60.88%. Given 2seventy bio's higher probable upside, equities analysts clearly believe 2seventy bio is more favorable than Cadrenal Therapeutics.
In the previous week, 2seventy bio had 4 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for 2seventy bio and 0 mentions for Cadrenal Therapeutics. 2seventy bio's average media sentiment score of 0.15 beat Cadrenal Therapeutics' score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media.
93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 7.2% of 2seventy bio shares are held by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cadrenal Therapeutics has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat Cadrenal Therapeutics' return on equity.
Summary
2seventy bio beats Cadrenal Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Cadrenal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cadrenal Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CVKD) was last updated on 2/22/2025 by MarketBeat.com Staff